Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ADK | P55263 | 5/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549902 | 0.90 | HTR2B (0.38) | HTR2BSIGMAR1ADKHTR1DTMEM97 | |
| SCHEMBL17549888 | 0.83 | HTR2B (0.31) | HTR2BSIGMAR1ADK | |
| SCHEMBL17549903 | 0.83 | HTR2B (0.31) | HTR2BSIGMAR1ADK | |
| SCHEMBL17549898 | 0.80 | PRMT5 (0.38) | ADK | |
| SCHEMBL18297616 | 0.77 | ADK (0.49) | ADKSLC29A1 | |
| SCHEMBL17536694 | 0.77 | NNMT (0.38) | — | |
| SCHEMBL31228243 | 0.77 | NNMT (0.38) | — | |
| SCHEMBL25048010 | 0.76 | ADK (0.45) | ADKSLC29A1 | |
| SCHEMBL30941231 | 0.76 | ADK (0.42) | ADKSLC29A1 | |
| SCHEMBL18297536 | 0.76 | ADK (0.42) | ADKSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458165-B2 | DOT1L inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060269-A1 | DOT1L Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060269-A1 | DOT1L Inhibitors | DOT1L, MAP1LC3B, MAP1LC3A | HTR2B 4616/4885SIGMAR1 4455/4885ADK 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.